AbbVie Inc (ABBV)
176.95
+5.22
(+3.04%)
USD |
NYSE |
Nov 22, 16:00
177.07
+0.12
(+0.07%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 312.70B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 32.50% |
| Valuation | |
| PE Ratio | 61.44 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 5.650 |
| Price to Book Value | 51.84 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.64 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 11.78 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 42.18% |
Profile
| AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox). |
| URL | http://www.abbvieinvestor.com |
| Investor Relations URL | https://investors.abbvie.com |
| HQ State/Province | Illinois |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Jan. 31, 2025 (est.) |
| Last Earnings Release | Oct. 30, 2024 |
| Next Ex-Dividend Date | Jan. 15, 2025 |
| Last Ex-Dividend Date | Oct. 15, 2024 |
Ratings
Profile
| AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox). |
| URL | http://www.abbvieinvestor.com |
| Investor Relations URL | https://investors.abbvie.com |
| HQ State/Province | Illinois |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Jan. 31, 2025 (est.) |
| Last Earnings Release | Oct. 30, 2024 |
| Next Ex-Dividend Date | Jan. 15, 2025 |
| Last Ex-Dividend Date | Oct. 15, 2024 |